Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) was upgraded by investment analysts at Zacks Research from a "hold" rating to a "strong-buy" rating in a note issued to investors on Tuesday, Zacks reports.
A number of other brokerages also recently issued reports on GYRE. Wall Street Zen raised Gyre Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, November 7th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Gyre Therapeutics in a research note on Wednesday, November 4th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy".
Get Our Latest Research Report on GYRE
Gyre Therapeutics Trading Down 4.8%
NASDAQ GYRE opened at $4.34 on Tuesday. The stock has a market capitalization of $500.49 million, a price-to-earnings ratio of -21.70 and a beta of 2.14. The stock has a 50-day moving average of $6.15 and a 200 day moving average of $6.76. Gyre Therapeutics has a twelve month low of $3.97 and a twelve month high of $9.14.
Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.19. The firm had revenue of $32.93 million for the quarter, compared to analysts' expectations of $28.40 million. Gyre Therapeutics had a negative net margin of 14.80% and a negative return on equity of 7.39%. Equities analysts predict that Gyre Therapeutics will post -0.34 EPS for the current fiscal year.
Institutional Trading of Gyre Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. SBI Securities Co. Ltd. increased its position in Gyre Therapeutics by 1.8% during the third quarter. SBI Securities Co. Ltd. now owns 169,717 shares of the company's stock worth $1,244,000 after buying an additional 2,967 shares in the last quarter. Bank of America Corp DE acquired a new position in Gyre Therapeutics during the second quarter valued at approximately $83,000. BlackRock Inc. acquired a new position in shares of Gyre Therapeutics during the second quarter worth about $6,550,000. Deutsche Bank AG acquired a new stake in Gyre Therapeutics during the 2nd quarter valued at $118,000. Finally, Bank of New York Mellon Corp acquired a new stake in Gyre Therapeutics during the 2nd quarter valued at approximately $414,000. Institutional investors and hedge funds own 23.99% of the company's stock.
About Gyre Therapeutics
(
Get Free Report)
Gyre Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for liver and other chronic diseases. The company operates in the United States and China, including through its China-based subsidiary, Beijing Continent Pharmaceuticals. Its pipeline includes hydronidone, also known as F351, an oral drug candidate being developed for liver fibrosis associated with chronic hepatitis B. Gyre is also developing treatments for other serious conditions, including acute-on-chronic liver failure.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.